Dengue vaccines: New developments

Drugs of the Future

Volumn 36, Issue 1, 2011, Pages 45-62

  Guzmán, María G ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DENGUE VACCINE; DENGUE VIRUS 2 MONOVALENT VACCINE; DNA SYNCON; DNA VACCINE; GAMMA INTERFERON; INACTIVATED VACCINE; LIVE VACCINE; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AEDES; AEDES AEGYPTI; AEDES ALBOPICTUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CLINICAL FEATURE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG DEVELOPMENT; EDEMA; EFFUSION; EYE PAIN; FEVER; HEMATOCRIT; HEPATOMEGALY; HUMAN; LETHARGY; LEUKOPENIA; LYMPHADENOPATHY; MYALGIA; NONHUMAN; PETECHIA; RASH; RESPIRATORY DISTRESS; RESTLESSNESS; REVIEW; SEROCONVERSION; SHOCK; THROMBOCYTOPENIA; VIRUS INACTIVATION; VOMITING;

EID: 84952978561     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.01.1583182     Document Type: Review

References (340)

1. Gubler, D.J. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 2002, 33(4): 330-42. (Pubitemid 35299553)
2. Guzman, M.G., Kouri, G. Dengue: An update. Lancet Infect Dis 2002, 2(1): 33-42.
3. Guzman, M.G., Halstead, S.B., Artsob, H. et al. Dengue: A continuing global threat. Nat Rev Microbiol 2010, S7-16.
4. WHO. Report of the Scientific Working Group meeting on Dengue. WHO: Geneva, Switzerland, 2006, 74-85.
5. Meltzer, M.I., Rigau Perez, J.G., Clark, G.G., Reiter, P., Gubler, D.J. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am J Trop Med Hyg 1998, 59(2): 265-71.
6. Beatty, M.E., Stone, A., Fitzsimons D.W. et al., for the Asia-Pacific and Americas Dengue Prevention Boards. Best practices in dengue surveillance: A report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis 2010, 4(11): e890.
7. PAHO. Dengue and dengue hemorrhagic fever in the Americas: Guidelines for prevention and control. Scientific Publication, Pan American Health Organization 1994, 548.
8. Gubler, D.J. The changing epidemiology of yellow fever and dengue, 1900 to 2003: Full circle? Comp Immunol Microbiol Infect Dis 2004, 27(5): 319-30.
9. Guzman, M.G., Kouri, G. Dengue and dengue hemorrhagic fever in the Americas: Lessons and challenges. J Clin Virol 2003, 27(1): 1-13. (Pubitemid 36513584)
10. San Martin, J.L., Brathwaite, O., Zambrano, B., Solórzano, J.O., Bouckenooghe, A., Dayan, G.H., Guzmán, M.G. The epidemiology of dengue in the americas over the last three decades: A worrisome reality. Am J Trop Med Hyg 2010, 82(1): 128-35.
11. Gubler, D. The emergence of epidemic dengue fever and dengue hemorrhagic fever in the Americas: A case of failed public health policy. Rev Panam Salud Publica 2005, 17(4): 221-4. (Pubitemid 40685803)
12. Vainio, K., Noraas, S., Holmberg, M., Fremstad, H., Wahlstrøm, M., Anestad, G., Dudman, S. Fatal and primary dengue virus infections imported to Norway from Africa and south-east Asia, 2008-2010. Euro Surveill 2010, 15(38): pii 19666.
13. Gubler, D.J., Sather, G.E., Kuno, G., Cabral, J.R. Dengue 3 virus transmission in Africa. Am J Trop Med Hyg 1986, 35(6): 1280-4. (Pubitemid 17210129)
14. WHO. Dengue. Guidelines for diagnosis, treatment, prevention and control. New edition. Geneva: World Health Organization, 2009.
15. WHO. Dengue in Africa: Emergence of DENV-3, Cote dívoire, 2008, Weekly epidemiological record 2009, (11/12): 85-7.
16. Franco, L., Di Caro, A., Carletti, F., Vapalahti, O., Zeller, H., Tenorio, A. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill 2010, 15(7): pii 19490.
17. Teo, D., Ng, L.C., Lam, S. Is dengue a threat to the blood supply? Transfus Med 2009, 19(2): 66-77.
18. Wilder-Smith, A., Chen, L.H., Massad, E., Wilson, M.E. Threat of dengue to blood safety in dengue-endemic countries. Emerg Infect Dis 2009, 15(1): 8-11.
19. Carme, B., Matheus, S., Donutil, G. et al. Concurrent dengue and malaria in Cayenne hospital, French Guiana. Emerg Infect Dis 2009, 15(4): 668-71.
20. Wilder-Smith, A., Gubler, D.J. Geographic expansion of dengue: The impact of international travel. Med Clin North Am 2008, 92(6): 1377-90.
21. Wilder-Smith, A., Deen, J.L. Dengue vaccines for travelers. Expert Rev Vaccines 2008, 7(5): 569-78. (Pubitemid 351881341)
22. Linnen, J.M., Vinelli, E., Sabino, E.C. et al. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008, 48(7): 1355-62.
23. La Ruche, G., Souarès, Y., Armengaud, A. et al. First two autochthonous dengue virus infections in metropolitan France, September 2010. Eurosurveillance 2010, 15(39): 1-5.
24. Anonymous. Locally acquired dengue-Key West Florida, 2009-2010. MMWR 2010, 59(19): 577-81.
25. Reiter, P. Yellow fever and dengue: A threat to Europe? Euro Surveill 2010, 15(10): 19509.
26. TDR/WHO. Report on dengue. TDR/Scientific Working Group: Geneva, Switzerland, 2006.
27. Farrar, J., Focks, D., Gubler, D. et al. Towards a global dengue research agenda. Trop Med Int Health 2007, 12(6): 695-9. (Pubitemid 46872786)
28. Henchal, E.A., Putnak, J.R. The dengue viruses. Clin Microbiol Rev 1990, 3(4): 376-96.
29. Rice, C.M. Flaviviridae: The viruses and their replication. In: Virology. Fields, B.M. (Ed.). Lippincott-Raven: Philadelphia/New York, 1996, 931-60.
30. Guirakhoo, F., Bolin, R.A., Roehrig, J.T. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 1992, 191(2): 921-31. (Pubitemid 23022496)
31. Heinz, F.X., Allison, S.L. Flavivirus structure and membrane fusion. Adv Virus Res 2003, 59: 63-97. (Pubitemid 137639364)
32. Clyde, K., Kyle, J.L., Harris, E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006, 80(23): 11418-31. (Pubitemid 44788858)
33. Harris, E., Holden, K.L., Edgil, D., Polacek, C., Clyde, K. Molecular biology of flaviviruses. Novartis Found Symp 2006, 277: 23-39; discussion 40, 71-3, 251-3.
34. Kuhn, R.J., Zhang, W., Rossmann, M.G. et al. Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell 2002, 108(5): 717-25. (Pubitemid 34241430)
35. Allison, S.L., Schalich, J., Stiasny, K., Mandl, C.W., Heinz, F.X. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 2001, 75(9): 4268-75. (Pubitemid 32410139)
36. Zhang, Y., Corver, J., Chipman, P.R. et al. Structures of immature flavivirus particles. EMBO J 2003, 22(11): 2604-13. (Pubitemid 36712358)
37. Zhang, W., Chipman, P.R., Corver, J. et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 2003, 10(11): 907-12. (Pubitemid 37386099)
38. Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C., Harrison, S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375(6529): 291-8.
39. Zhang, Y., Zhang, W., Ogata, S. et al. Conformational changes of the flavivirus e glycoprotein. Structure (Camb) 2004, 12(9): 1607-18. (Pubitemid 39200514)
40. Chua, J.J., Ng, M.M., Chow, V.T. The non-structural 3 (NS3) protein of dengue virus type 2 interacts with human nuclear receptor binding protein and is associated with alterations in membrane structure. Virus Res 2004, 102(2): 151-63. (Pubitemid 38490331)
41. Li, H., Clum, S., You, S., Ebner, K.E., Padmanabhan, R. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol 1999, 73(4): 3108-16. (Pubitemid 29135701)
42. 42, Nomaguchi, M., Ackermann, M., Yon, C. et al. De novo synthesis of negative-strand RNA by dengue virus RNA-dependent RNA polymerase in vitro: Nucleotide, primer, and template parameters. J Virol 2003, 77(16): 8831-42. (Pubitemid 36936095)
43. Tan, B.H., Fu, J., Sugrue, R.J. et al. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 1996, 216(2): 317-25. (Pubitemid 26083377)
44. Lindenbach, B.D., Rice, C.M. Molecular biology of flaviviruses. Adv Virus Res 2003, 59: 23-61. (Pubitemid 137639363)
45. Rothman, A.L. Immunology and immunopathogenesis of dengue disease. Adv Virus Res 2003, 60: 397-419.
46. Rothman, A.L. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010, 338: 83-98.
47. Rico-Hesse, R. Microevolution and virulence of dengue viruses. Adv Virus Res 2003, 59: 315-41.
48. Cologna, R., Rico-Hesse, R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003, 77(7): 3929-38. (Pubitemid 36350934)
49. Armstrong, P.M., Rico-Hesse, R. Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis 2001, 1(2): 159-68.
50. Rodriguez-Roche, R., Alvarez, M., Gritsun, T. et al. Virus evolution during a severe dengue epidemic in Cuba, 1997. Virology 2005, 334(2): 154-9.
51. Rodriguez-Roche, R., Alvarez, M., Gritsun, T. et al. Dengue virus type 2 in Cuba, 1997: Conservation of E gene sequence in isolates obtained at different times during the epidemic. Arch Virol 2005, 150(3): 415-25.
52. Guzman, M.G., Deubel, V., Pelegrino, J.L. et al. Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic. Am J Trop Med Hyg 1995, 52(3): 241-6.
53. Guzman, M.G., Vazquez, S., Martinez, E. et al. Dengue in Nicaragua, 1994: Reintroduction of serotype 3 in the Americas. Rev Panam Salud Publica 1997, 1(3): 193-9.
54. Guzman, M.G., Kouri, G. Dengue haemorrhagic fever integral hypothesis: Confirming observations, 1987-2007. Trans R Soc Trop Med Hyg 2008, 102(6): 522-3.
55. Messer, W.B., Gubler, D.J., Harris, E., Sivananthan, K., de Silva, A.M. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 2003, 9(7): 800-9. (Pubitemid 36801579)
56. Rico-Hesse, R., Harrison, L.M., Salas, R.A. et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997, 230(2): 244-51. (Pubitemid 27211855)
57. Kouri, G.P., Guzman, M.G., Bravo, J.R. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans R Soc Trop Med Hyg 1987, 81(5): 821-3.
58. Alvarez, M., Guzman, M.G., Rosario, D. et al. Secuenciacion directa de un producto amplificado de una muestra de suera. [Direct sequencing of an amplified product from a serum sample]. Rev Cubana Med Trop 1996, 48(1): 53-5.
59. Sariol, C.A., Pelegrino, J.L., Martinez, A. et al. Detection and genetic relationship of dengue virus sequences in seventeen-year-old paraffin-embedded samples from Cuba. Am J Trop Med Hyg 1999, 61(6): 994-1000. (Pubitemid 30084127)
60. Diaz, F.J., Black, W.Ct., Farfan-Ale, J.A. et al. Dengue virus circulation and evolution in Mexico: A phylogenetic perspective. Arch Med Res 2006, 37(6): 760-73. (Pubitemid 43975170)
61. Guzman, M.G., Vazquez, S., Martinez, E. et al. Dengue en Nicaragua, 1994: Reintroduccion del serotipo 3 en las Americas. [Dengue in Nicaragua, 1994: Reintroduction of serotype 3 in the Americas]. Bol Oficina Sanit Panam 1996, 121(2): 102-10.
62. Bennett, S.N., Holmes, E.C., Chirivella, M. et al. Selection-driven evolution of emergent dengue virus. Mol Biol Evol 2003, 20(10): 1650-8. (Pubitemid 41070827)
63. Perez-Ramirez, G., Diaz-Badillo, A., Camacho-Nuez, M., Cisneros, A., Munoz Mde, L. Multiple recombinants in two dengue virus, serotype-2 isolates from patients from Oaxaca, Mexico. BMC Microbiol 2009, 9: 260.
64. Twiddy, S.S., Holmes, E.C. The extent of homologous recombination in members of the genus Flavivirus. J Gen Virol 2003, 84(Pt. 2): 429-40. (Pubitemid 36175718)
65. Twiddy, S.S., Holmes, E.C., Rambaut, A. Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol 2003, 20(1): 122-9. (Pubitemid 36077906)
66. Holmes, E.C., Twiddy, S.S. The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 2003, 3(1): 19-28. (Pubitemid 36437583)
67. Holmes, E.C., Burch, S.S. The causes and consequences of genetic variation in dengue virus. Trends Microbiol 2000, 8(2): 74-7. (Pubitemid 30100330)
68. Guzman, M.G., Kouri, G., Halstead, S.B. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics? Lancet 2000, 355(9218): 1902-3.
69. Wang, W.K., Lin, S.R., Lee, C.M., King, C.C., Chang, S.C. Dengue type 3 virus in plasma is a population of closely related genomes: Quasispecies. J Virol 2002, 76(9): 4662-5.
70. Wittke, V., Robb, T., Thu, H. et al. Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period. Virology 2002, 301(1): 148-56. (Pubitemid 35168510)
71. Rudnick, A., Marchette, N.J., Garcia, R. Possible jungle dengue - Recent studies and hypotheses. Jpn J Med Sci Biol 1967, 20(Suppl.): 69-74.
72. Rodhain, F. The role of monkeys in the biology of dengue and yellow fever. Comp Immunol Microbiol Infect Dis 1991, 14(1): 9-19.
73. Wolfe, N.D., Kilbourn, A.M., Karesh, W.B. et al. Sylvatic transmission of arboviruses among Bornean orangutans. Am J Trop Med Hyg 2001, 64(5-6): 310-6.
74. Rudnick, A. Ecology of dengue virus. Asian J Infect Dis 1978, 2: 156-60. (Pubitemid 10087780)
75. Wang, E., Ni, H., Xu, R. et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol 2000, 74(7): 3227-34. (Pubitemid 30143747)
76. Vasilakis, N., Tesh, R.B., Weaver, S.C. Sylvatic dengue virus type 2 activity in humans, Nigeria, 1966. Emerg Infect Dis 2008, 14(3): 502-4.
77. Cardosa, J., Ooi, M.H., Tio, P.H. et al. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient with dengue hemorrhagic fever. PLoS Negl Trop Dis 2009, 3(4): e423.
78. Vasilakis, N., Cardosa, J., Diallo, M., Holmes, E.C., Hanley, K.A., Weaver, S.C. Sylvatic dengue viruses share the pathogenic potential of urban/endemic dengue viruses. J Virol 2010, 84(7): 3726-8.
79. WHO. Dengue hemorrhagic fever. Diagnosis, treatment, prevention and control. Geneva, 1997, 1-84.
80. Gould, E.A., Solomon, T. Pathogenic flaviviruses. The Lancet 2008, 371: 500-9. (Pubitemid 351199886)
81. Rigau-Perez, J.G. Severe dengue: The need for new case definitions. Lancet Infect Dis 2006, 6(5): 297-302.
82. Deen, J.L., Harris, E., Wills, B. et al. The WHO dengue classification and case definitions: Time for a reassessment. Lancet 2006, 368(9530): 170-3. (Pubitemid 43994174)
83. Bandyopadhyay, S., Lum, L.C., Kroeger, A. Classifying dengue: A review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop Med Int Health 2006, 11(8): 1238-55. (Pubitemid 44125713)
84. WHO. Clinical dengue classification. WHO Dengue Guidelines, 2010.
85. Halstead, S.B. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 1970, 42(5): 350-62.
86. Halstead, S.B., Lan, N.T., Myint, T.T. et al. Dengue hemorrhagic fever in infants: Research opportunities ignored. Emerg Infect Dis 2002, 8(12): 1474-9. (Pubitemid 36008787)
87. Halstead, S. Overview and history. In: Dengue. Scott, B.H. (Ed.). Imperial College Press: Singapore, 2008, 19.
88. Libraty, D.H., Acosta, L.P., Tallo, V. A prospective nested case-control study of dengue in infants: Rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2010, 6(10): 1-11.
89. Halstead, S.B., Udomsakdi, S., Scanlon, J.E., Rohitayodhin, S. Dengue and Chikungunya virus infection in man in Thailand, 1962-1964. V. Epidemiologic observations outside Bangkok. Am J Trop Med Hyg 1969, 18(6): 1022-33.
90. Halstead, S.B. Antibodies determine virulence in dengue. Ann N Y Acad Sci 2009, 1171(Suppl. 1): E48-56.
91. Halstead, S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003, 60: 421-67.
92. Halstead, S. Pathophysiology. In: Dengue. Scott, B.H. (Ed.). Imperial College Press: London, 2008, 285-326.
93. Burke, D.S., Nisalak, A., Johnson, D.E., Scott, R.M. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988, 38(1): 172-80. (Pubitemid 18036130)
94. Graham, R.R., Juffrie, M., Tan, R. et al. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. Studies in 1995-1996. Am J Trop Med Hyg 1999, 61(3): 412-9. (Pubitemid 29428712)
95. Guzman, M.G., Kouri, G.P., Bravo, J. et al. Dengue hemorrhagic fever in Cuba, 1981: A retrospective seroepidemiologic study. Am J Trop Med Hyg 1990, 42(2): 179-84.
96. Fried, J.R., Gibbons, R.V., Kalayanarooj, S. et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: An analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 2010, 4(3): e617.
97. Guzman, M.G., Kouri, G., Valdes, L. et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 2000, 152(9): 793-9; discussion 804.
98. Sierra, B., Kouri, G., Guzman, M.G. Race: A risk factor for dengue hemorrhagic fever. Arch Virol 2007, 152(3): 533-42. (Pubitemid 46363592)
99. Sierra, B., Alegre, R., Perez, A.B. et al. HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: Advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol 2007, 68(6): 531-40. (Pubitemid 46726862)
100. Bravo, J.R., Guzman, M.G., Kouri, G.P. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 1987, 81(5): 816-20.
101. Halstead, S.B., Streit, T.G., Lafontant, J.G. et al. Haiti: Absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001, 65(3): 180-3. (Pubitemid 32847807)
102. Loke, H., Bethell, D., Phuong, C.X. et al. Susceptibility to dengue hemorrhagic fever in Vietnam: Evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. Am J Trop Med Hyg 2002, 67(1): 102-6. (Pubitemid 35034327)
103. Sakuntabhai, A., Turbpaiboon, C., Casademont, I. et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005, 37(5): 507-13. (Pubitemid 40617279)
104. Garcia, G., Sierra, B., Perez, A.B. et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcyRIIa polymorphism. Am J Trop Med Hyg 2010, 82(6): 1153-6.
105. Chaturvedi, U., Nagar, R., Shrivastava, R. Dengue and dengue haemorrhagic fever: Implications of host genetics. FEMS Immunol Med Microbiol 2006, 47(2): 155-66. (Pubitemid 43881735)
106. Guzman, M.G., Kouri, G., Bravo, J. et al. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002, 6(2): 118-24. (Pubitemid 34793060)
107. Guzman, M.G., Kouri, G., Valdes, L. et al. Enhanced severity of secondary dengue-2 infections: Death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002, 11(4): 223-7.
108. Alvarez, M., Rodriguez-Roche, R., Bernardo, L. et al. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg 2006, 75(6): 1113-7. (Pubitemid 351627493)
109. Rico-Hesse, R. Dengue virus evolution and virulence models. Clin Infect Dis 2007, 44(11): 1462-6. (Pubitemid 46801591)
110. Rico-Hesse, R. Dengue virus markers of virulence and pathogenicity. Fut Virol 2009, 4(6): 581.
111. Leitmeyer, K.C., Vaughn, D.W., Watts, D.M. et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999, 73(6): 4738-47. (Pubitemid 29246733)
112. Sabin, A.B. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1(1): 30-50.
113. Guzman, M.G., Alvarez, M., Rodriguez-Roche, R. et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 2007, 13(2): 282-6. (Pubitemid 46193173)
114. Sierra, B., Garcia, G., Perez, A.B. et al. Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis 2002, 6(2): 125-8. (Pubitemid 34793061)
115. Halstead, S.B. Etiologies of the experimental dengue of Siler and Simmons. Am J Trop Med Hyg 1974, 23(5): 974-82.
116. Okuno, Y., Fukunaga, T., Tadano, M. et al. Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. Biken J 1983, 26(4): 161-3.
117. Halstead, S.B. Immune enhancement of viral infection. Prog Allergy 1982, 31: 301-64.
118. Halstead, S.B. Dengue. Lancet 2007, 370(9599): 1644-52.
119. Libraty, D.H., Endy, T.P., Houng, H.S. et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002, 185(9): 1213-21. (Pubitemid 34439127)
120. Vaughn, D.W., Green, S., Kalayanarooj, S. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181(1): 2-9. (Pubitemid 30049026)
121. Mas, P. Dengue fever in Cuba in 1977. PAHO 1978, 375: 40-3.
122. Kouri, G., Guzman, M.G., Valdes, L. et al. Reemergence of dengue in Cuba: A 1997 epidemic in Santiago de Cuba. Emerg Infect Dis 1998, 4(1): 89-92.
123. Kouri, G.P., Guzman, M.G., Bravo, J.R., Triana, C. Dengue haemorrhagic fever/dengue shock syndrome: Lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989, 67(4): 375-80.
124. Valdes, L., Guzman, M.G., Kouri, G. et al. La epidemiologia del dengue y del dengue hemorragico en Santiago de Cuba, 1997. [Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997]. Rev Panam Salud Publica 1999, 6(1): 16-25.
125. Pelaez, O., Guzmán, M.G., Kourí, G. et al. Dengue 3 epidemic in Havana, 2001. Emerg Infect Dis 2004, 10(4): 219-22.
126. Cummings, D.A.T., Schwartz, I.B., Billings, I., Shaw, L.B., Burke, D.S. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A 2005, 102(42): 15259-64. (Pubitemid 41513369)
127. Henchal, E.A., McCown, J.M., Burke, D.S., Seguin, M.C., Brandt, W.E. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg 1985, 34(1): 162-9. (Pubitemid 15174332)
128. Pierson, T.C., Diamond, M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008, 10: e12.
129. King, N.J., Getts, D.R., Getts, M.T. et al. Immunopathology of flavivirus infections. Immunol Cell Biol 2007, 85(1): 33-42.
130. Rodenhuis-Zybert, I.A., van der Schaar, H.M., da Silva Voorham, J.M. et al. Immature dengue virus: A veiled pathogen? PLoS Pathog 2010, 6(1): e1000718.
131. Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979): 745-8.
132. Guzman, M.G., Vazquez, S. The complexity of antibody dependent enhancement of dengue virus infection. Viruses 2010, 2: 2649-62.
133. Rothman, A.L. Dengue: Defining protective versus pathologic immunity. J Clin Invest 2004, 113(7): 946-51.
134. Rothman, A.L., Ennis, RA. Immunopathogenesis of dengue hemorrhagic fever. Virology 1999, 257(1): 1-6.
135. Kurane, I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 2007, 30(5-6): 329-40. (Pubitemid 47450087)
136. Green, S., Rothman, A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006, 19(5): 429-36. (Pubitemid 44338101)
137. Mongkolsapaya, J., Dejnirattisai, W., Xu, X.N. et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9(7): 921-7. (Pubitemid 36889936)
138. Mongkolsapaya, J., Duangchinda, T., Dejnirattisai, W. et al. T cell responses in dengue hemorrhagic Fever: Are cross-reactive T cells suboptimal? J Immunol 2006, 176(6): 3821-9. (Pubitemid 43364031)
139. Green, S., Vaughn, D.W., Kalayanarooj, S. et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 1999, 179(4): 755-62. (Pubitemid 29159319)
140. Duangchinda, T., Dejnirattisai, W., Vasanawathana, S. et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A 2010, 107(39): 16922-7.
141. Beaunier, C.M., Rothman, A.C. Cross-reactive memory CD4+ T cells alter the CD8+T cell response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. Viral Immunol 2009, 22(3): 215-9.
142. Fink, J., Gu, F., Vasudevan, S.G. Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev Med Virol 2006, 16(4): 263-75. (Pubitemid 44140722)
143. Perez, A.B., Garcia, G., Sierra, B. et al. IL-10 levels in Dengue patients: Some findings from the exceptional epidemiological conditions in Cuba. J Med Virol 2004, 73(2): 230-4. (Pubitemid 38542677)
144. Lee, Y.R., Liu, M.T., Lei, H.Y. et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 2006, 87(Pt. 12): 3623-30. (Pubitemid 44816994)
145. Avila-Aguero, M.L., Avila-Aguero, C.R., Um, S.L. et al. Systemic host inflammatory and coagulation response in the dengue virus primo-infection. Cytokine 2004, 27(6): 173-9. (Pubitemid 39078524)
146. Mustafa, A.S., Elbishbishi, E.A., Agarwal, R., Chaturvedi, U.C. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2001, 30(3): 229-33. (Pubitemid 32373298)
147. Perez, A.B., Sierra, B., Garcia, G. et al. Tumor necrosis factor-alpha transforming growth factor-1, and interleukin-1 gene polymorphisms: Implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol 2010, 71(11): 1135-40.
148. Huang, Y.H., Lei, H.Y., Liu, H.S. et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol 2003, 70(4): 610-6.
149. Warke, R.V., Xhaja, K., Martin, K.J. et al. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J Virol 2003, 77(21): 11822-32. (Pubitemid 37271679)
150. Jessie, K., Fong, M.Y., Devi, S., Lam, S.K., Wong, K.T. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 2004, 189(8): 1411-8. (Pubitemid 38543590)
151. Jain, A., Chaturvedi, U.C. Dengue in infants: An overview. FEMS Immunol Med Microbiol 2010, 59(2): 119-30.
152. Sierra, B., Perez, A.B., Vogt, K. et al. Secondary heterologous dengue infection risk: Disequilibrium between immune regulation and inflammation. Cell Immunol 2010, 262(2): 134-40.
153. Falconar, A.K. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997, 142(5): 897-916. (Pubitemid 27218413)
154. Lei, H.Y., Yeh, T.M., Liu, H.S. et al. Immunopathogenesis of dengue virus infection. J Biomed Sci 2001, 8(5): 377-88.
155. Lin, C.F., Lei, H.Y, Shiau, A.L. et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 2003, 69(1): 82-90.
156. Lin, C.F., Wan, S.W., Cheng, H.J., Lei, H.Y., Lin, Y.S. Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006, 19(2): 127-32.
157. Lin, C.F., Wan, S.W., Chen, M.C. et al. Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Lab Invest 2008, 88(10): 1079-89.
158. Sun, D.S., King, C.C., Huang, H.S. et al. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. J Thromb Haemost 2007, 5(11): 2291-9.
159. Chungue, E., Poli, L., Roche, C. et al. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J Infect Dis 1994, 170(5): 1304-7. (Pubitemid 24328643)
160. Huang, Y.H., Chang, B.I., Lei, H.Y. et al. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol 1997, 110(1): 35-40. (Pubitemid 27428512)
161. Markoff, L.J., Innis, B.L., Houghten, R., Henchal, L.S. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. J Infect Dis 1991, 164(2): 294-301.
162. Malasit, P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health 1987, 18(3): 316-20.
163. Avirutnan, P., Mehlhop, E., Diamond, M.S. Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine 2008, 26(Suppl. 8): 1100-7.
164. Avirutnan, P., Punyadee, N., Noisakran, S. et al. Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193(8): 1078-88.
165. Cologna, R., Armstrong, P.M., Rico-Hesse, R. Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 2005, 79(2): 853-9. (Pubitemid 40053868)
166. Nielsen, D.G. The relationship of interacting immunological components in dengue pathogenesis. Virol J 2009, 6: 211.
167. Chaturvedi, U.C., Agarwal, R., Elbishbishi, E.A., Mustafa, A.S. Cytokine cascade in dengue hemorrhagic fever: Implications for pathogenesis. FEMS Immunol Med Microbiol 2000, 28(3): 183-8. (Pubitemid 32939398)
168. Guzman, M.G., Mune, M., Kouri, G. Dengue vaccine: Priorities and progress. Expert Rev Anti Infect Ther 2004, 2(6): 895-911.
169. Simmons, C.P., Farrar, J. Changing patterns of dengue epidemiology and implications for clinical management and vaccines. PLoS Med 2009, 6(9): e1000129.
170. Hombach, J. Vaccines against dengue: A review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica 2007, 21(4): 254-60. (Pubitemid 47147601)
171. Hombach, J., Barrett, A.D., Cardosa, M.J. et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2005, 23(21): 2689-95. (Pubitemid 40381260)
172. Stephenson, J.R. Understanding dengue pathogenesis: Implications for vaccine design. Bull World Health Organ 2005, 83(4): 308-14. (Pubitemid 40529628)
173. Bente, D.A., Rico-Hesse, R. Models of dengue virus infection. Drug Discov Today Dis Models 2006, 3(1): 97-103.
174. Plotkin, S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001, 20(1): 63-75. (Pubitemid 32066180)
175. Falconar, A.K. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: Design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 1999, 144(12): 2313-30.
176. Vazquez, S., Guzman, M.G., Guillen, G. et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002, 20(13-14): 1823-30. (Pubitemid 34242839)
177. Crill, W.D., Roehrig, J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001, 75(16): 7769-73. (Pubitemid 32738039)
178. Crill, W.D., Chang, G.J. Localization and characterization of flavivirus
179. Goncalvez, A.P., Men, R., Wernly, C., Purcell, R.H., Lai, C.J. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol 2004, 78(23): 12910-8. (Pubitemid 39507799)
180. Goncalvez, A.P., Purcell, R.H., Lai, C.J. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 2004, 78(23): 12919-28. (Pubitemid 39507800)
181. Roehrig, J.T., Bolin, R.A., Kelly, R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246(2): 317-28. (Pubitemid 28384045)
182. Sukupolvi-Petty, S., Austin, S.K., Purtha, W.E. et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007, 81(23): 12816-26. (Pubitemid 350156919)
183. Hatch, S., Mathew, A., Rothman, A. Dengue vaccine: Opportunities and challenges. IDrugs 2008, 11(1): 42-5.
184. Vaughn, D.W., Scherer, J.M., Sun, W. Resistance to infection. In: Dengue. Halstead, S.B. (Ed.). Imperial College Press: London, 2008, 123-69.
185. Rothman, A.L, Kanesa thasan, N., West, K. et al. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001, 19(32): 4694-9.
186. Mathew, A., Rothman, A. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008, 225: 300-13.
187. Guy, B. Immunogenicity of Sanofi Pasteur tetravalent dengue vaccine. J Clin Virol 2009, 46(Suppl. 2): S16-9.
188. Thomas, S.J., Hombach, J., Barrett, A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009, 27(3): 355-68.
189. Putnak, R., Barvir, D.A., Burrous, J.M. et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996, 174(6): 1176-84. (Pubitemid 26393894)
190. Maves, R.C., Castillo Ore, R.M., Porter, K.R., Kochel, T.J. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin Vaccine Immunol 2010, 17(2): 304-6.
191. Putnak, R.J., Coller, B.A., Voss, G. et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23(35): 4442-52. (Pubitemid 40991230)
192. Brandt, W.E.; from the World Health Organization. Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses. J Infect Dis 1988, 157(5): 1105-11.
193. Kinney, R.M., Huang, C.Y. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 2001, 44(2-3): 176-97. (Pubitemid 32757396)
194. Innis, B.L., Eckels, K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003, 69(6, Suppl.): 1-4.
195. Wisseman, C.L. Jr., Sweet, B.H., Rosenzweig, E.C., Eylar, O.R. Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg 1963, 12: 620-3.
196. Sabin, A.B., Schlesinger, R.W. Production of immunity to dengue with virus modified by propagation in mice. Science 1945, 101(2634): 640-2.
197. Innis, B.L., Eckels, K.H., Kraiselburd, E. et al. Virulence of a live dengue virus vaccine candidate: A possible new marker of dengue virus attenuation. J Infect Dis 1988, 158(4): 876-80.
198. Eckels, K.H., Brandt, W.E., Harrison, V.R., McCown, J.M., Russell, P.K. Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun 1976, 14(5): 1221-7.
199. Eckels, K.H., Harrison, V.R., Summers, P.L., Russell, P.K. Dengue-2 vaccine: Preparation from a small-plaque virus clone. Infect Immun 1980, 27(1): 175-80. (Pubitemid 10211953)
200. Bancroft, W.H., Top, F.H. Jr., Eckels, K.H. et al. Dengue-2 vaccine: Virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun 1981, 31(2): 698-703. (Pubitemid 11146250)
201. Scott, R.M., Nisalak, A., Eckels, K.H. et al. Dengue-2 vaccine: Viremia and immune responses in rhesus monkeys. Infect Immun 1980, 27(1): 181-6. (Pubitemid 10211954)
202. Scott, R.M., Eckels, K.H., Bancroft, W.H. et al. Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status. J Infect Dis 1983, 148(6): 1055-60. (Pubitemid 14206309)
203. Halstead, S.B., Marchette, N.J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: Studies at the University of Hawaii. Am J Trop Med Hyg 2003, 69(6, Suppl.): 5-11.
204. Sun, W., Edelman, R., Kanesa-Thasan, N. et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69(6, Suppl.): 24-31.
205. Edelman, R., Wasserman, S.S., Bodison, S.A. et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003, 69(6, Suppl.): 48-60.
206. Kanesa-Thasan, N., Edelman, R., Tacket, C.O. et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: Selection of safe and immunogenic monovalent vaccines. Am J Trap Med Hyg 2003, 69(6, Suppl.): 17-23.
207. Sun, W., Cunningham, D., Wasserman, S.S. et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009, 5(1): 33-40.
208. Simasathien, S., Thomas, S.J., Watanaveeradej, V. et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008, 78(3): 426-33.
209. Sardelis, M.R., Edelman, R., Klein, T.A. et al. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus. Am J Trop Med Hyg 2000, 62(6): 698-701.
210. Bhamarapravati, N., Sutee, Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000, 18(Suppl. 2): 44-7.
211. Bhamarapravati, N., Yoksan, S., Chayaniyayothin, T., Angsubphakom, S., Bunyaratvej, A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987, 65(2): 189-95.
212. Kanesa-thasan, N., Sun, W., Kim-Ahn, G. et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19(23-24): 3179-88.
213. Sabchareon, A., Lang, J., Chanthavanich, P. et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66(3): 264-72.
214. Kitchener, S., Nissen, M., Nasveld, R et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24(9): 1238-41.
215. Sanchez, V., Gimenez, S., Tomlinson, B. et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vera cells (VDV3). Vaccine 2006, 24(23): 4914-26.
216. Sabchareon, A., Lang, J., Chanthavanich, P. et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004, 23(2): 99-109.
217. Seligman, S.J., Gould, E.A. Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis 2008, 198(5): 794-5.
218. Monath, T.P., Kanesa-Thasan, N., Guirakhoo, F. et al. Recombination and flavivirus vaccines: A commentary. Vaccine 2005, 23(23): 2956-8.
219. Butrapet, S., Huang, C.Y., Pierro, D.J. et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol 2000, 74(7): 3011-9.
220. Rice, C.M., Grakoui, A., Galler, R., Chambers, T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1989, 1(3): 285-96.
221. Lai, C.J., Zhao, B.T., Hori, H., Bray, M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A 1991, 88(12): 5139-43.
222. Puri, B., Polo, S., Hayes, C.G., Falgout, B. Construction of a full length infectious clone for dengue 1 virus Western Pacific, 74 strain. Virus Genes 2000, 20: 57-63.
223. Guirakhoo, F., Arroyo, J., Pugachev, K.V. et al. Construction, safety and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75(16): 7290-304.
224. Guirakhoo, F., Pugachev, K., Arroyo, J. et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002, 298(1): 146-59.
225. Guirakhoo, F., Pugachev, K., Zhang, Z. et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(9): 4761-75.
226. Monath, T.P., Myers, G.A., Beck, R.A. et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33(3): 131-44.
227. Johnson, B.W., Chambers, T.V., Crabtree, M.B. et al. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 2004, 70(1): 89-97.
228. McGee, C.E., Tsetsarkin, K., Vanlandingham, D.L. et al. Substitution of mild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does hot enhance infection of Aedes aegypti mosquitoes. J Infect Dis 2008, 197(5): 686-92.
229. Brandler, S., Brown, N., Ermak, T.H. et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 2005, 72(1): 74-81.
230. Guirakhoo, F., Kitchener, S., Morrison, D. et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2(2): 60-7.
231. Guy, B., Saville, M., Lang, J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010, 6(9): 696-705.
232. Morrison, D., Legg, T.J., Billings, C.W. et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201(3): 370-7.
233. Poo, M.D., Galan, F., Forrat, R., Zambrano, B., Lang, J., Dayan, G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents and adults in Mexico city. Pediatr Infect Dis J 2010, 30(1): 1-9.
234. Bray, M., Lai, C.J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci U S A 1991, 88(22): 10342-6.
235. Bray, M., Lai, C.J. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 1991, 185(1): 505-8.
236. Bray, M., Men, R., Lai, C.J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 1996, 70(6): 4162-6.
237. Chen, W., Kawano, H., Men, R., Clark, D., Lai, C.J. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 1995, 69(8): 5186-90.
238. Lai, C.J., Bray, M., Men, R. et al. Evaluation of molecular strategies to develop a live dengue vaccine. Clin Diagn Virol 1998, 10(2-3): 173-9.
239. Cahour, A., Pletnev, A., Vazielle Falcoz, M., Rosen, L., Lai, C.J. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 1995, 207(1): 68-76.
240. Men, R., Bray, M., Clark, D., Chanock, R.M., Lai, C.J. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996, 70(6): 3930-7.
241. Troyer, J.M., Hanley, K.A., Whitehead, S.S. et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001, 65(5): 414-9.
242. Durbin, A.R, Karron, R.A., Sun, W. et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001, 65(5): 405-13.
243. Durbin, A.P., Whitehead, S.S., McArthur, J. et al. rDEN4 Delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005, 191(5): 710-8.
244. Wright, P.F., Durbin, A.P., Whitehead, S.S. et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN430-4995 in healthy adult volunteers. Am J Trop Med Hyg 2009, 81(5): 834-41.
245. Whitehead, S.S., Falgout, B., Hanley, K.A. et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003, 77(2): 1653-7.
246. Durbin, A.P., McArthur, J., Marron, J.A. et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2006, 2(4): 167-73.
247. Durbin, A.P., McArthur, J.H., Marron, J.A. et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006, 2(6): 255-60.
248. Blaney, J.E. Jr., Sathe, N.S., Hanson, C.T. et al. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol J 2007, 4: 23.
249. Blaney, J.R. Jr., Hanson, C.T., Hanley, K.A., Murphy, B.R., Whitehead, S.S. Vaccine candidates derived from a novel infections cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 2004, 4: 39.
250. Blaney, J.E. Jr., Hanson, C.T., Firestone, C.Y., Hanley, K.A., Murphy, B.R., Whitehead, S.S. Genetically modified live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004, 71(6): 811-21.
251. Whitehead, S.S., Hanley, K.A., Blaney, J.E. et al. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003, 21(27-28): 4307-16.
252. Blaney, J.E. Jr., Matro, J.M., Murphy, B.R., Whitehead, S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005, 79(9): 5516-28.
253. Blaney, J.E. Jr., Sathe, N.S., Goddard, L. et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4. Vaccine 2008, 26(6): 817-28.
254. Kinney, R.M., Butrapet, S., Chang, G.J. et al. Construction of infectious cDNA clones for dengue 2 virus: Strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997, 230(2): 300-8.
255. Huang, C.Y., Butrapet, S., Pierro, D.J. et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000, 74(7): 3020-8.
256. Huang, C.Y., Butrapet, S., Tsuchiya, K.R. et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003, 77(21): 11436-47.
257. Anonymous. WHO convenes meeting on dengue modeling. PDVI News 2010, 8: 1-2.
258. Caufour, P.S., Motta, M.C., Yamamura, A.M. et al. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 2001, 79(1-2): 1-14.
259. Galler, R., Marchevsky, R.S., Caride, E. et al. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys. Braz J Med Biol Res 2005, 38(12): 1835-46.
260. Suzuki, R., Winkelmann, E.R., Mason, P.W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J Virol 2009, 83(4): 1870-80.
261. Costa, S.M., Paes, M.V., Barreto, D.F. et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006, 24(2): 195-205.
262. Raviprakash, K., Kochel, T.J., Ewing, D. et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000, 18(22): 2426-34.
263. Raviprakash, K., Porter, K.R., Kochel, T.J. et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000, 81(Pt. 7): 1659-67.
264. Raviprakash, K., Ewing, D., Simmons, M. et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003, 315(2): 345-52.
265. Kochel, T.J., Raviprakash, K., Hayes, C.G. et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18(27): 3166-73.
266. Kochel, T., Wu, S.J., Raviprakash, K. et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15(5): 547-52.
267. Porter, K.R., Kochel, T.J., Wu, S.J. et al. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 1998, 143(5): 997-1003.
268. Raviprakash, K., Apt, D., Brinkman, A. et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006, 353(1): 166-73.
269. Apt, D., Raviprakash, K., Brinkman, A. et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006, 24(3): 335-44.
270. Konishi, E., Kosugi, S., Imoto, J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006, 24(12): 2200-7.
271. Imoto, J., Konishi, E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 2007, 25(6): 1076-84.
272. Ramanathan, M.P., Kuo, Y.C., Selling, B.H. et al. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009, 27(46): 6444-53.
273. Mota, J., Acosta, M., Argotte, R. et al. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005, 23(26): 3469-76.
274. Wu, S.F., Liao, C.L., Lin, Y.L. et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003, 21(25-26): 3919-29..
275. Costa, S.M., Azevedo, A.S., Paes, M.V. et al. DNA vaccines against dengue virus based on the ns1 gene: The influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 2007, 358(2): 413-23.
276. Costa, S.M., Freire, M.S., Alves, A.M. DNA vaccine against the non-structural 1 protein (NSl) of dengue 2 virus. Vaccine 2006, 24(21): 4562-4.
277. Mellado-Sanchez, G., Garcia-Machorro, J., Sandoval-Montes, C. et al. A Plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model. Arch Virol 2010, 155(6): 847-56.
278. Mota-Sanchez. Vacunas de ADN: Inducción de la respuesta inmunitaria. Salud Publica Mex 2009, 51: S463-9.
279. Restifo, N.P., Ying, H., Huang, L., Leitner, W.W. The promise of nuclei acid vaccines. Gene Ther 2000, 7(2): 89-92.
280. Gurunathan, S., Klinman, D.M., Seder, R.A. DNA vaccines: Immunology, application and optimization. Annu Rev Immunol 2000, 18: 927-74.
281. Jechlinger, W. Optimization and delivery of plasmid DNA for vacination. Expert Rev Vaccines 2006, 5(6): 803-25.
282. Guzman, M.G., Rodriguez, R., Hermida, L. et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaco fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 2003, 69(2): 129-34.
283. Mune, M., Rodriguez, R., Ramirez, R. et al. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to dengue 4 virus challenge in mice. Arch Virol 2003, 148(11): 2267-73.
284. Wei, H., Jiang, L., Xue, Y., Fang, D., Guo, H. Secreted expression of dengue virus type 2 full-length envelope glycoprotein in Pichia pastoris. J Virol Methods 2003, 109(1): 17-23.
285. Simmons, M., Murphy, G.S., Hayes, C.G. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001, 65(2): 159-61.
286. Saejung, W., Puttikhunt, C., Prommool, T. et al. Enhancement of recombinant soluble dengue virus 2 envelope domain III protein production in Escherichia coli trxB and gor double mutant. J Biosci Bioeng 2006, 102(4): 333-9.
287. Guzman, M.G., Hermida, L., Bernardo, L., Ramirez, R., Guillen, C. Domain III of the envelope protein as a dengue vacine target. Expert Rev Vaccines 2010, 9(9): 87-97.
288. Simmons, M., Porter, K.R., Escamilla, J. et al. Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Am J Trop Med Hyg 1998, 58(2): 144-51.
289. Simmons, M., Murphy, G.S., Kochel, T., Raviprakash, K., Hayes, C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg 2001, 65(5): 420-6.
290. Khanam, S., Etemad, B., Khanna, N., Swaminathan, S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains iii of these two serotypes. Am J Trop Med Hyg 2006, 74(2): 266-77.
291. Leng, C.H., Liu, S.J., Tsai, J.P. et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 2009, 11(2): 288-95.
292. Zhang, Z.S., Yan, Y.S., Weng, Y.W. et al. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J Virol Methods 2007, 143(2): 125-31.
293. Batra, G., Talha, S.M., Nemani, S.K. et al. Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen. Protein Expr Purif 2010, 4(1): 99-105.
294. Bernardo, L., Izquierdo, A., Alvarez, M. et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 2008, 80(2): 194-9.
295. Bernardo, L., Fleitas, O., Pavon, A. et al. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol 2009, 16(12): 1829-31.
296. Hermida, L., Rodriguez, R., Lazo, L. et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004, 115(1): 41-9.
297. Hermida, L., Rodriguez, R., Lazo, L. et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 2004, 39(Pt. 1): 107-14.
298. Hermida, L., Bernardo, L., Martin, J. et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006, 24(16): 3165-71.
299. Izquierdo, A., Bernardo, L., Martin, J. et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 2008, 138(1-2): 135-8.
300. Valdes, I., Hermida, L., Martin, J. et al. Immunological evaluation in non-human primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009, 27(7): 995-1001.
301. Lazo, L., Zulueta, A., Hermida, L. et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 2009, 52(Pt. 4): 265-71.
302. Chen, H.W., Liu, S.J., Liu, H.H. et al. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 2009, 27(9): 1400-9.
303. Clements, D.E., Coller, B.A., Lieberman, M.M. et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(15): 2705-15.
304. Anonymous. Progress in dengue vaccine development. PDVI News 2010, (8): 7.
305. Raviprakash, K., Defang, G., Burgess, T., Porter, K. Advances in dengue vaccine development. Hum Vaccin 2009, 5(8): 520-8.
306. Alcon, S., Talarmin, A., Debruyne, M. et al. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 2002, 40(2): 376-81.
307. Guillen, G., Aguilar, J.C., Duenas, S. et al. Virus-like particles as vaccine antigens and adjuvants: Application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. Procedia Vaccinology 2010, 2: 128-33.
308. Bisht, H., Chugh, D.A., Raje, M., Swaminathan, S.S., Khanna, N. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J Biotechnol 2002, 99(2): 97-110.
309. Amexis, G., Young, N.S. Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus. J Infect Dis 2006, 194(6): 790-4.
310. Gil, L., Lopez, C., Lazo, L. et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol 2009, 21(10): 1175-83.
311. Valdes, I., Bernardo, L., Gil, L. et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009, 394(2): 249-58.
312. Lazo, L., Hermida, L., Zulueta, A. et al. A recombinant capsid protein from dengue-2 induces protection in mice against homologous virus. Vaccine 2007, 25(6): 1064-70.
313. Spohn, G., Jennings, G.T., Martina, B.E. et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 2010, 7; 146.
314. Men, R., Wyatt, L., Tokimatsu, I. et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000, 18(27): 3113-22.
315. Despres, P., Combredet, C., Frenkiel, M.P. et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191(2): 207-14.
316. Brandler, S., Lucas-Hourani, M., Moris, A. et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007, 1(3): e96.
317. Brandler, S., Ruffie, C., Najburg, V., Frenkiel, M.P., Bedouelle, H., Despres, P., Tangy, F. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010, 28(41): 6730-9.
318. Holman, D.H., Wang, D., Raviprakash, K. et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 2007, 14(2): 182-9.
319. Raja, N.U., Holman, D.H., Wang, D. et al. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am J Trop Med Hyg 2007, 76(4): 743-51.
320. Khanam, S., Pilankatta, R., Khanna, N., Swaminathan, S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27(43): 6011-21.
321. Khanam, S., Rajendra, P., Khanna, N., Swaminathan, S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 2007, 7: 10.
322. Lin, J., Calcedo, R., Vandenberghe, L.H., Figueredo, J.M., Wilson, J.M. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 2008, 19(7): 663-9.
323. Shepard, D.S., Suaya, J.A., Halstead, S.B. et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 2004, 22(9-10): 1275-80.
324. Guy, B., Barban, V., Mantel, N. et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(2): 302-11.
325. Raviprakash, K., Defang, G., Burgess, T., Porter, K. Advances in dengue vaccine development. Hum Vaccin 2009, 5(8): 520-8.
326. Chen, L., Ewing, D., Subramanian, H. et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 2007, 81(21): 11634-9.
327. Valdes, I., Hermida, L., Gil, L. et al. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis 2009, 14(5): e377-83.
328. Simmons, M., Burgess, T., Lynch, J., Putnak, R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010, 396(2): 280-8.
329. Mahoney, R.T. Dengue vaccine adoption in developing countries: Some cost and financing issues. PDVI Occasional paper 1 (July), 2010, 1-8.
330. Hanna, J. Dengue vaccines: Introduction and delivery issues. PDVI Occasional paper 2 (September), 2010, 1-23.
331. Almond, J., Clemens, J., Engers, H. et al. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. Vaccine 2002, 20(25-26): 3043.
332. Halstead, S.B., Deen, J. The future of dengue vaccines. Lancet 2002, 360(9341): 1243-5.
333. Hombach, J. Guidelines for clinical trials of dengue vaccine in endemic areas. J Clin Virol 2009, 46(Suppl. 2): S7-9.
334. Edelman, R., Hombach, J. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": Summary of a World Health Organization Technical Consultation. Vaccine 2008, 26(33): 4113-9.
335. Hombach, J., Cardosa, M.J., Sabchareon, A., Vaughn, D.W., Barrett, A.D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007, 25(21): 4130-9.
336. Roehrig, J.T., Hombach, J., Barrett, A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21(2): 123-32.
337. WHO. State of the art of new vaccine research and development. WHO/IVB/06.01, 2006.
338. Durbin, A.P., Whitehead, S.S. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010, 338: 129-43.
339. Gonzalez, D., Castro, O., Perez, J. et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis 2005, 9(5): 280-5.
340. Loke, H., Bethell, D.B., Phuong, C.X. et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: A double-edged sword? J Infect Dis 2001, 184(11): 1369-73